Kaoru Funabashi

633 total citations
11 papers, 475 citations indexed

About

Kaoru Funabashi is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Kaoru Funabashi has authored 11 papers receiving a total of 475 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 4 papers in Pulmonary and Respiratory Medicine and 4 papers in Oncology. Recurrent topics in Kaoru Funabashi's work include Lung Cancer Treatments and Mutations (4 papers), HER2/EGFR in Cancer Research (3 papers) and Fibroblast Growth Factor Research (2 papers). Kaoru Funabashi is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), HER2/EGFR in Cancer Research (3 papers) and Fibroblast Growth Factor Research (2 papers). Kaoru Funabashi collaborates with scholars based in Japan, United States and France. Kaoru Funabashi's co-authors include Toshihiko Saeki, Takahiro Fukuroda, Takehiro Fukami, Masaki Ihara, Mitsuo Yano, Hiroyuki Suda, Kiyofumi Ishikawa, Hirokazu Ohsawa, Satoru Ito and Takeshi Sagara and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Kaoru Funabashi

11 papers receiving 464 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kaoru Funabashi Japan	9	283	132	125	110	66	11	475
Maria Valentine United States	11	201 0.7×	140 1.1×	78 0.6×	93 0.8×	111 1.7×	13	694
Charles W. Bruseo Switzerland	10	519 1.8×	87 0.7×	167 1.3×	52 0.5×	31 0.5×	16	679
Olivier Defert Belgium	8	352 1.2×	66 0.5×	87 0.7×	42 0.4×	58 0.9×	14	677
Heidi R. Hope United States	9	366 1.3×	94 0.7×	56 0.4×	24 0.2×	55 0.8×	13	528
Weiwei Li China	14	281 1.0×	31 0.2×	227 1.8×	96 0.9×	91 1.4×	44	631
Thirumagal Thiyagarajan United States	15	339 1.2×	63 0.5×	76 0.6×	201 1.8×	10 0.2×	23	617
Sophie Beyer United States	9	394 1.4×	127 1.0×	46 0.4×	75 0.7×	69 1.0×	11	687
Sanna-Kaisa Häkkinen Finland	8	284 1.0×	58 0.4×	35 0.3×	66 0.6×	87 1.3×	9	591
Shin‐Shay Tian United States	14	200 0.7×	51 0.4×	41 0.3×	55 0.5×	39 0.6×	18	740

Countries citing papers authored by Kaoru Funabashi

Since Specialization

Citations

This map shows the geographic impact of Kaoru Funabashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaoru Funabashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaoru Funabashi more than expected).

Fields of papers citing papers by Kaoru Funabashi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaoru Funabashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaoru Funabashi. The network helps show where Kaoru Funabashi may publish in the future.

Co-authorship network of co-authors of Kaoru Funabashi

This figure shows the co-authorship network connecting the top 25 collaborators of Kaoru Funabashi. A scholar is included among the top collaborators of Kaoru Funabashi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaoru Funabashi. Kaoru Funabashi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Ito, Satoru, Sachie Otsuki, Hirokazu Ohsawa, et al.. (2023). Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use. ACS Medicinal Chemistry Letters. 14(4). 396–404. 16 indexed citations

Tsuji, Shingo, Masayuki Nakamura, Akihiro Miura, et al.. (2022). TAS2940, a novel brain‐penetrable pan‐ERBB inhibitor, for tumors with HER2 and EGFR aberrations. Cancer Science. 114(2). 654–664. 8 indexed citations

Sootome, Hiroshi, Hidenori Fujita, Kenjiro Ito, et al.. (2020). Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors. Cancer Research. 80(22). 4986–4997. 137 indexed citations

Udagawa, Hibiki, Akihiro Ohashi, Naomi Abe, et al.. (2019). TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations. Molecular Cancer Research. 17(11). 2233–2243. 55 indexed citations

Irie, Hiroki, Kimihiro Ito, Akio Fujioka, et al.. (2019). TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models. Molecular Cancer Therapeutics. 18(4). 733–742. 12 indexed citations

Kawai, Yuichi, Satoshi Yamashita, Hiromi Oshiumi, et al.. (2018). Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor. Journal of Medicinal Chemistry. 62(2). 531–551. 48 indexed citations

Fujita, Hidenori, Isao Miyazaki, Masanori Kato, et al.. (2018). Abstract 4784: TAS0286/HM05, a novel highly selective RET inhibitor, prominently inhibits various RET defective tumor growth. Cancer Research. 78(13_Supplement). 4784–4784. 1 indexed citations

Sunami, T., Noel Byrne, Ronald E. Diehl, et al.. (2009). Structural Basis of Human p70 Ribosomal S6 Kinase-1 Regulation by Activation Loop Phosphorylation. Journal of Biological Chemistry. 285(7). 4587–4594. 46 indexed citations

Kera, Yoshio, et al.. (1996). d-Aspartyl residue in a peptide can be liberated and metabolized by pig kidney enzymes. Amino Acids. 10(2). 187–196. 5 indexed citations

10.

Ihara, Masaki, Kiyofumi Ishikawa, Takahiro Fukuroda, et al.. (1992). In Vitro Biological Profile of a Highly Potent Novel Endothelin (ET) Antagonist BQ-123 Selective for the ETA Receptor. Journal of Cardiovascular Pharmacology. 20. S11–S14. 102 indexed citations

11.

Ihara, M., Toshihiko Saeki, Kaoru Funabashi, et al.. (1991). Two Endothelin Receptor Subtypes in Porcine Arteries. Journal of Cardiovascular Pharmacology. 17. S119–121. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact